A Pilot Study to Evaluate the Effects of Siddha Drug Ciṟupīḷaikkuṭinīr in Microalbuminuria Patients
Ancient Science of Life · 2025-01 · 39 (2) · 199-208
DOI: 10.4103/asl.asl_75_25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Ancient Science of Life, online erschienen am 16.07.2026. Verfasst von G. S. Lekha und 4 weiteren Autor:innen. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Context
Diabetic nephropathy is one of the major microvascular complications of diabetes mellitus and a leading cause of end-stage renal disease. There is a growing interest in identifying safe, cost-effective herbal interventions for early management of Nephropathy.
Aim
This study evaluates the efficacy of the Siddha herbal formulation Ciṟupīḷaikkuṭinīr (Decoction of Aerva lanata (L.) Juss. ex Schult.) in patients with early-stage diabetic nephropathy. Settings and Design: An open-label, interventional, prospective, single-arm pilot trial conducted in Siddha Clinical Research Institute. Materials and Methods: Twelve patients diagnosed with early-stage diabetic nephropathy were enrolled and completed both treatment and follow-up phases. The intervention consisted of the administration of Ciṟupīḷaikkuṭinīr for a period of 1 month. Primary outcome measures included estimated glomerular filtration rate (eGFR), urinary albumin-creatinine ratio, blood urea and Serum creatinine levels. Secondary outcomes were symptomatic relief and quality of life assessed using the Kidney Disease Quality of Life-36 (KDQOL-36) questionnaire.
Results
All participants reported symptom improvement that persisted beyond the treatment phase. eGFR increased in 8 patients (67%) following treatment and during follow-up. A sustained reduction in blood urea was observed in six patients (50%). All participants showed improved KDQOL-36 scores posttreatment, with notable gains in the physical component summary, symptoms and problems of kidney disease, and effects of kidney disease subdomains.
Conclusion
Ciṟupīḷaikkuṭinīr appears to be a safe and showed the trend towards improvement in renal function and quality of life in early-stage diabetic nephropathy subjects. These findings warrant further investigation through larger, randomized controlled trials to confirm efficacy and evaluate long-term outcomes.
Zitieren
APA
Lekha, G. S., Parvathy, P., Aparna, S., Vinod, N. P., & Kanagarajan, A. (2025). A Pilot Study to Evaluate the Effects of Siddha Drug Ciṟupīḷaikkuṭinīr in Microalbuminuria Patients. Ancient Science of Life, 39(2), 199-208. https://doi.org/10.4103/asl.asl_75_25
Vancouver
Lekha GS, Parvathy P, Aparna S, Vinod NP, Kanagarajan A. A Pilot Study to Evaluate the Effects of Siddha Drug Ciṟupīḷaikkuṭinīr in Microalbuminuria Patients. Ancient Science of Life. 2025;39(2):199-208. doi:10.4103/asl.asl_75_25
BibTeX
@article{Lekha2025,
author = {Lekha, G. S. and Parvathy, P. and Aparna, S. and Vinod, N. P. and Kanagarajan, A.},
title = {A Pilot Study to Evaluate the Effects of Siddha Drug Ciṟupīḷaikkuṭinīr in Microalbuminuria Patients},
journal = {Ancient Science of Life},
year = {2025},
volume = {39},
number = {2},
pages = {199--208},
doi = {10.4103/asl.asl_75_25}
}
EUVIMED